L
Lukas A. Oomen
Researcher at Genmab
Publications - 2
Citations - 853
Lukas A. Oomen is an academic researcher from Genmab. The author has contributed to research in topics: Cytotoxic T cell & Daratumumab. The author has an hindex of 2, co-authored 2 publications receiving 722 citations.
Papers
More filters
Journal ArticleDOI
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
Michel de Weers,Yu-Tzu Tai,Michael S. van der Veer,Joost M. Bakker,Tom Vink,Daniëlle C H Jacobs,Lukas A. Oomen,Matthias Peipp,Thomas Valerius,Jerry W. Slootstra,Tuna Mutis,Wim K. Bleeker,Kenneth C. Anderson,Henk M. Lokhorst,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Paul W. H. I. Parren +16 more
TL;DR: The results show the versatility of daratumumab to effectively kill CD38-expressing tumor cells, including patient MM cells, via diverse cytotoxic mechanisms, and support clinical development of darsatumab for the treatment of CD 38-positive MM tumors.
Journal ArticleDOI
Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.
Yu-Tzu Tai,Michel de Weers,Xian-Feng Li,Weihua Song,Sabikun Nahar,Joost M. Bakker,Tom Vink,Daniëlle C H Jacobs,Lukas A. Oomen,Wim K. Bleeker,Nikhil C. Munshi,Jan G. J. van de Winkel,Paul W. H. I. Parren,Paul G. Richardson,Kenneth C. Anderson +14 more
TL;DR: The results indicate that daratumumab is able to effectively kill patient MM tumor cells via several cytotoxic mechanisms, supporting clinical development of daratuzumab to improve patient outcome in MM.